Acute and chronic effects of two different intravenous iloprost (ILO) regimens in systemic sclerosis: a pragmatic non–randomized trial. ILO had an acute effect as assessed by power Doppler US and by contrast, an ILO chronic effect was not detectable before the following infusion in both treatment groups. PubMed, Rheumatology (Oxford), 05/03/2018.
The safety of iloprost (ILO) in systemic sclerosis in a real–life experience. Our data suggest that calcium channel blockers should be transitorily stopped while using ILO and that a pre–treatment approach might reduce or control adverse events. PubMed, Clin Rheumatol, 02/22/2018.
Comparative Safety and Tolerability of Prostacyclins (PG12) in Pulmonary Hypertension (PAH). The development of PGI2 analogues has improved survival in patients with PAH and remains the main treatment option in advanced disease. PubMed, Drug Saf, 2016 Apr;39(4):287-94. (Also see Scleroderma Treatments - General)
Role of Vasodilator Testing in Pulmonary Hypertension (PAH). To identify patients who are likely to have a beneficial response to calcium channel blockers (CCBs) and therefore a better prognosis, acute vasodilator testing should be performed in patients in certain subsets of PAH. PubMed, Prog Cardiovasc Dis, 2016 Jan-Feb;58(4):425-33. (Also see Scleroderma Treatments - General)
Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study. In this observational study of patients with pulmonary hypertension receiving combination therapy with iloprost and sildenafil, cumulative transplant–free survival was highest in those who received iloprost monotherapy initially. PubMed, BMC Pulm Med, 2016 Jan 12;16:5. (Also see Treatments for Pulmonary Arterial Hypertension: PDE-5 Inhibitors)
Iloprost reverses established fibrosis in experimental right ventricular (RV) failure. Inhaled iloprost improves RV function and reverses established RV fibrosis partially by preventing collagen synthesis and by increasing collagen turnover. PubMed, Eur Respir J, 2015 Feb;45(2):449-62. (Also see Scleroderma Treatments - General)
Case Study: Possible anti–metastatic effect of Iloprost in a patient with systemic sclerosis (SSc) with lung cancer. Herein, we report iloprost treatment of a 60-year-old-woman with SSc, who lately developed pulmonary hypertension as a complication of her disease and lung adenocarcinoma as a co-incidence simultaneously. Yavuz Pehlivan, Reheumatology International. (Also see Cancer)
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: